RT Journal Article
SR Electronic
T1 Emergence and spread of the potential variant of interest (VOI) B.1.1.519 predominantly present in Mexico
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.18.21255620
DO 10.1101/2021.05.18.21255620
A1 Abril Paulina Rodríguez-Maldonado
A1 Joel Armando Vázquez-Pérez
A1 Alberto Cedro-Tanda
A1 Blanca Taboada
A1 Celia Boukadida
A1 Claudia Wong-Arámbula
A1 Tatiana Ernestina Nuñez-García
A1 Natividad Cruz-Ortiz
A1 Gisela Barrera-Badillo
A1 Lucía Hernández-Rivas
A1 Irma López-Martínez
A1 Alfredo Mendoza-Vargas
A1 Juan Pablo Reyes-Grajeda
A1 Nicolas Alcaraz
A1 Fernando Peñaloza-Figueroa
A1 Dulibeth Gonzalez-Barrera
A1 Daniel Rangel-DeLeon
A1 Luis Alonso Herrera-Montalvo
A1 Fidencio Mejía-Nepomuceno
A1 Alejandra Hernández-Terán
A1 Mario Mújica-Sánchez
A1 Eduardo Becerril-Vargas
A1 José Arturo Martínez-Orozco
A1 Rogelio Pérez-Padilla
A1 Jorge Salas-Hernández
A1 Alejandro Sanchez-Flores
A1 Pavel Isa
A1 Margarita Matías-Florentino
A1 Santiago Ávila-Ríos
A1 José Esteban Muñoz-Medina
A1 Concepción Grajales-Muñiz
A1 Angel Gustavo Salas-Lais
A1 Andrea Santos Coy-Arechavaleta
A1 Alfredo Hidalgo-Miranda
A1 Carlos F. Arias
A1 José Ernesto Ramírez-González
YR 2021
UL http://medrxiv.org/content/early/2021/05/20/2021.05.18.21255620.abstract
AB SARS-CoV-2 variants have emerged in late 2020 and there are at least three variants of concern (B.1.1.7, B.1.351, P1) reported by WHO. These variants have several substitutions in the Spike protein that affect receptor binding; they present increased transmissibility and may be associated with reduced vaccine effectiveness. In the present work, we are reporting the identification of a potential variant of interest harboring the mutations T478K, P681H, and T732A in the Spike protein, within the newly named lineage B.1.1.519, which rapidly outcompeted the preexisting variants in Mexico and has been the dominant virus in the country during the first trimester of 2021.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was partially supported by grants Epidemiologia Genomica de los Virus SARS-CoV-2 Circulantes en Mexico and Caracterizacion de la diversidad viral y bacteriana" from the National Council for Science and Technology (CONACyT) of Mexico to C.F.A. and J.A.V.P. respectively and also grants 057, 047 and 072 from the Ministry of Education, Science, Technology and Innovation (SECTEI) of Mexico City to C.F.A., L.H.M. y A.H.M. respectivelyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Residual RNA positive samples were recovered and sequenced from routine SARS CoV-2 diagnostic and were processed following Standardized Guideline for Epidemiological and Laboratory surveillance of Viral Respiratory Disease (https://www.gob.mx/cms/uploads/attachment/file/610162/Lineamiento_VE_y_Lab_Enf_Viral_Ene-2021_290121.pdf) emitted and approved by the CONAVE (National Counsel of Epidemiology Surveillance) of the Secretariat of Health, Government of Mexico. This work was also approved for the Ethics Committee on Research of the National Institute of Genomic Medicne with the registration number of the National Bioethics Commission CONBIOETICA-09-CEI-008-20180615 under the opinion number CEI 2020/20. All data obtained in this work are directly related to disease control and were openly available at the GISAID website to the public before the initiation of the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available on GISAID website https://www.gisaid.org/